African Journal of Advanced Pure and Applied Sciences (AJAPAS)

Volume 1, Issue 2, April 2022, Page No: 1-6
Website: https://aaasjournals.com/index.php/ajapas/index

Oral Delivery of Biologics: Recent Advances, Challenges, and Future Perspectives

Hamza Khalifa[1], Noor-Alhooda Milood Al-Awkally[2], Salwa Muftah Eljamay[3]
[1] Pharmacy Department, Higher Institute of medical Technology, Bani Walid, Libya
[2] Medical laboratory Department, Higher Institute of Science and Technology, Suluq, Libya
[3] Health Department, College of Medical Technology, Derna, Libya

[*]*Corresponding author: hamzakhlifa2009@gmail.com*

Article history
Received : February 15, 2022
Accepted : March 29, 2022
Published : April 02, 2022

Keywords:
Biologics
Oral delivery
Advancements
Challenges
Future predictions
Intestine

Abstract: Biologics are the biopharmaceutical drugs that come into existence through biological processes and sources. Today, biologics are the most propitious drugs for the oral dose of various diseases. These diseases can be concerning metabolism and inflammation disorders. Oral delivery of biologics has proven to be the most attainable method of providing medication. It has been highly effective because patients are seen to be directed towards the oral medication because of the ease in taking doses. Despite biologicals being the most promising drug, there are still many hurdles that occur in the oral delivery of them due to several severe harsh boundaries. The sensitivity and the difficulty in delivery of the biologics via the gastrointestinal tract are the biggest hurdles. The research on the oral delivery of biologicals is the most studied topic and is still under the research of many researchers, as it is proven to be pivotal for gaining the desired results from the drug for good.

Cite this article as: H. Khalifa, N. M. Al-Awkally, S. M. Eljamay, "Oral Delivery of Biologics: Recent Advances, Challenges, and Future Perspectives," *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, Vol. 1, Issue 2, pp. 1-6, 2022.

Introduction

Biologics are known as medicines that are produced from living organisms which can be peptides, vaccines, and proteins. Almost hundreds of years have passed since biologics came into the healthcare department as the use of medications. The oral delivery of biologicals is to be studied for various reasons and requirements. It is one of the most auspicious ways of oral delivery of the antibiotic [1]. The research concerning the history of oral biologics has rich and detailed information available. Biologics are completely different from traditional medicines in form of their structure, chemical formula, efficacy, storage, administration, and cost. Biologics are known to be extremely complex and sensitive to the environment of the gastrointestinal tract. Hence, they are ought to be kept in an optimum environment for safety [2]. Biologics are said to be the most preferred alternate traditional medicines due to their convenience. There are several types of biologics being delivered from the oral passage in the human body. Hence, to check the delivery and its characteristics, it is important to know about the advancements, changes, and technological challenges being occurred in the way of oral conveyance of biological drugs to comprehend these insights, this paper will talk about the

advancements, challenges, and the future predictions pertinent to oral delivery of biologics. Further, it will talk about the various routes of oral delivery administration, among them the major one is, the gastrointestinal tract.



Figure 1 Oral Delivery of Biologics for Precision Medicine [3].

Recent Advancements in Oral Delivery of Biologics

Biologics being declared as the modern solution to the diseases, such as bowel disease, inflammatory disease, diabetes, and cancer is provided with higher importance. It has been studied that in 2018 almost eight out of ten medications sold in America appeared to be Biologics. With the amalgamation of the recent advancements, the research of oral delivery of biologics is increasing the clinical drug technologies. Several advancements were made to enhance the efficiency of the medications. The first and foremost advancement was to protect biologics from acidic and enzymatic degradation. It occurred by having a collaboration of proteins and peptides with inhibitors, which helps to modify the chemical structure of the biologics and improve the stability of the fluids in the gastrointestinal tract. This strategy of advancement has been made possible by an innovation process of cyclization approach. Another major advancement is the increased time of the biologic with the absorptive epithelium, this helps in the prevention of luminal loss from the biologic and is said to be consisting vital enhancement of absorption of the medicine in the gastrointestinal tract. The third advancement made for the betterment of oral biologic delivery is making the mucosal barrier highly permeable. This strategy improves and enhances the oral bioavailability of the biologics due to the modification of the intestinal mucous barrier and epithelial barrier. It further helps in the diffusion of the bigger molecule of biologics. The fourth advancement in the field of oral delivery of biologic is, to increase the permeability of the delivery system of biologic. It briefs that the oral delivery system of the biologic helps in better absorption of the medication within the body, hence, improving the efficacy and efficiency of the medicine leading to the reduction of diseases in the body. Biologics have also seen further advancements and success. Around 30% of the drugs approved by the US Food and Drug Administration were biologics the years 2015-2018. Today almost 60 peptides are being approved by the administration; this is twice the number previously being approved. The table below shows the oral administration overview of the biologics [4]. The growing success of biologics within days is expected to be dedicated to the safety and regulation of biologics. These advancements are successful and are proven to be making biologics the most promising drug among all the conventional medications.

The Dose and Size of Biologics Dependency to Dictate Delivery Strategy

The molecular mass of the biologic and the size are considered for the development of alternative strategies for non-invasive delivery. The absorption is dependent on the size and the dose of biologic, specifically for the ones that require the bigger dose. The higher dose of the biologic with the same structure consists of a different rate of diffusion in comparison to the lower dose as the concentration acts as the catalyst of the absorption. In addition to this, every delivery site has specific characteristics and properties, therefore the limitations of diffusion are specific to each site. To have an idea about the sites, it is important to have an understanding of biological barriers. These understandings are important for the execution of alternative and invasive routes of oral deliveries, diffusion, and absorption. These are also important to achieve 100 percent bioavailability. The clinical advancements have also created the facility approach for the large volume subcutaneous injections, and commercial approaches have been made to facilitate the delivery.

Table. 1. Overview of biologics administration [4].

Route of Absorption	Advantages	Disadvantages	Challenges	Biologic Delivery System
Intravenous	100% bioavailability Reproducibility	Painful injection Needs medical personnel	None	Various peptides and antibodies are approved by clinical experts
Subcutaneous	Self-administered Avoids first pass metabolism	Painful	Extra cellular Limited space of injection	Several proteins and antibodies given orally.
Transdermal	Self-administered Non invasive	Transport barriers Slow absorption	Stratum corneum. Shedding of cells constantly. Lipid bilayers surround coenocytes.	Several vaccines that are given to human beings.
Oral	Self-administered Non invasive	Chemical environment is harsh. Easy degradation	Mucus Bacteria Gastric issues Acid Enzymes Protease Epithelial cells	Insulin as capsules given to diabetic patients..
Inhaled	Rapid absorption Large surface of absorption Non invasive	Dosing variability	Surfactant Mucus Macrophages	Insulin as dry powder.

Buccal	Non invasive Rapid absorption Avoid first pass metabolism	Less area for absorption Irrigation is likely to occur	Mucus Epithelial cells	Insulin as buccal films.
Nasal	Non invasive Self-administered Rapid absorption	Less area for absorption Irrigation is likely to occur	Mucus Epithelial cells	Several vaccines. Eg: nasal spray

Challenges Faced In The Way Of Oral Delivery of Biologics

Despite having numerous propitious and enormous benefits with amazing results the biologics delivery faced some challenges on the path of advancements, these challenges faced are as followed:

- The carriers based on nanoparticle have low therapeutic capacity.
- The capacity of delivery is also a hurdle as the biological ways are destroyed by systems with low capacity.
- The attachment and absorption of the material is also an issue, as it gets difficult to occur as a basic intestinal fluid constituent.

These challenges occurred in the way of oral delivery systems of biologics created the issues as the poor permeability affected the pathway. Hence created adverse impact on the overall delivery of the drug.



Figure 2. Oral Delivery of Biologics for Precision Medicine [5]

Future Perspective of Oral Delivery of Biologics

Several approaches in order to make civil agreement oral biologics have been made in order to create a bright future for the delivery of biologics [6]. One of the best examples of these approaches that help in the success in the future certainty of biologics are polymeric micro-particle depots and hyaluronidases. These approaches and systems are highly favourable as these includes release that is under control and physically helps in separating biologics from

subcutaneous microenvironment. It also helps in improving the dispersion for hyaluronidases. Since it has also been studied that the size of the biologic 3 years and adverse impact on the diffusion and absorption of biologics hence they have not proven to be effective for the delivery route which results in insignificant diffusion and absorptions hurdles. Before in order to reduce these problems some novel approaches are made to to make the absorption larger and more effective for the future biologics. In addition to this there have been several future work on transdermal biologics as well. The developments of non-invasive delivery has also been introduced, this has given the initial insights to analyse that which approach is highly suitable with larger biologics and works best for future advancements. Developments are further made for the antibodies use in the future [7]. Collectively, all the transdermal developments have worked in best possible manner to be sustainable and reliable in the future. Furthermore, the approaches of development in the injectable has also played a vital role in the future perspective of the biologics. The majority of these injectables are tend to be working for the diabetic issues in the future. The work has also been done on the bioavailability of these drugs in the shape of enhancements of peptides other antibodies. The future also holds the sustainable production, high efficiency and lower cost of these biologics for example, an oral aspect of desmopressin acetate. The future perspective also indicates that, the factories producing living organisms are highly prone to provide enormous benefits that non-living product or factories are unable to provide such as they are able to provide permanent in non-permanent colonisation in the natural capabilities. Pulmonary delivery is also developing to be executed in the large area with more permeability in the alveolar epithelium. New technologies are ought to be delivered which would reduce all the complexities [8]. There has been more to the future developments, such as, improvement of controlled release drug delivery vehicles and executing technologies for drugs that have inefficient bio pharmaceutical properties and customised strategies for specific population are developed. There also have been several advancements to remove difficulties and complexities of secure and efficient delivery deeply inside the lungs. All these future perspectives and advances of oral delivery of biologics play a vital role in the acceptance of the biologics clinically. Despite having the challenges and hurdles the biologics did get some future stability in their fate which made it possible to make these inventions of each biologic possible.

Oral conveyance of enormous peptides and proteins is an undertaking, which has grown up. With various different clinical preliminaries showing progress as far as adequacy, there will certainly be items available in the following couple of years, and the variables restricting their appearance will not be specialised, to such an extent as financial and calculated [9]. Costs for huge scope assembling of biologics have descended fundamentally over the most recent couple of years; the way that main a piece of the payload is conveyed across the stomach is presently not an issue, and bio potency levels of 10% are adequate to yield items that are profoundly reasonable from a monetary point of view. While a plague according to the conveyance perspective, the high proteolytic action in the stomach implies that any material that is not brought up is quickly separated into non-poisonous parts, thus no wellbeing issues are raised. The shift of accentuation in this manner moves to the idea of the vehicle, which may frequently offset the API by a variable of ten to 1,000. Excipients that are modest, GRAS-recorded or pharmacopoeial, stable and have a decent security record are obviously beneficial. Biologics as of now assume a significant part in the therapy of illness, in regions like diabetes (insulin, GLP-1) osteoporosis (sCT and PTH) and rheumatoid joint pain (TNF bar) and therapy of these, and other constant problems, will before long be changed by the appearance of the up-coming techniques portrayed here for their conveyance as oral drugs [10].

Conclusion

The swift growth and approval to use biologics in clinical requirements has changed the manner of drug delivery. It has been transferred from conventional manner to the contemporary oral manner. This transfer of drug delivery from conventional to traditional has made it possible for the clinical representatives to eliminate the challenges by introducing new strategies and all the needs and requirement criteria has been fulfilled. The contribution in the field of biologics has focus on analysing and evaluating the criteria for storage, diffusion, and permeability and residence time for injectable to enhance absorption of biologics. The research and studies carried out for the matter of oral delivery of biologics has contributed enormously in the progress of drugs. The high effectiveness of psychological barriers in gastrointestinal tract in approach to safe delivery has also been studied in the paper to analyse the safe approaches. The amalgamation of advancements, challenges and future of biologics has played a vital role to make it a promising drug.

References

[1] R. New, "Oral Delivery of Biologics via the Intestine," Pharmaceutics, vol. 13, no. 1, p. 18, Dec. 2020.

[2] J. Mantaj and D. V. author D. Vllasaliu, "Recent Advances in the Oral Delivery of Biologics," The Pharmaceutical Journal, 2020.

[3] M. Durán-Lobato, Z. Niu, and M. J. Alonso, "Oral Delivery of Biologics for Precision Medicine," Advanced Materials (Deerfield Beach, Fla.), vol. 32, no. 13, p. e1901935, Apr. 2020.

[4] A. C. Anselmo, Y. Gokarn, and S. Mitragotri, "Non-invasive Delivery Strategies for Biologics," Nature Reviews Drug Discovery, vol. 18, no. 1, pp. 19–40, Nov. 2018.

[5] "Oral Drug Delivery: Oral Delivery of Biologics for Precision Medicine," Pharma Excipients, Apr. 07, 2020.

[6] D. Vllasaliu, M. Thanou, S. Stolnik, and R. Fowler, "Recent Advances in Oral Delivery of biologics: Nanomedicine and Physical Modes of Delivery," Expert Opinion on Drug Delivery, vol. 15, no. 8, pp. 759–770, Aug. 2018, doi: 10.1080/17425247.2018.1504017.

[7] E. Caffarel-Salvador, A. Abramson, R. Langer, and G. Traverso, "Oral Delivery of Biologics Using drug-device Combinations," Current Opinion in Pharmacology, vol. 36, pp. 8–13, Oct. 2017, doi: 10.1016/j.coph.2017.07.003.

[8] E. Mühlberg, M. Burtscher, F. Umstätter, G. Fricker, W. Mier, and P. Uhl, "Trends in Liposomal Nanocarrier Strategies for the Oral Delivery of Biologics," Nanomedicine, vol. 16, no. 20, pp. 1813–1832, Aug. 2021, doi: 10.2217/nnm-2021-0177.

[9] R. New, "Oral Delivery of Biologics via the Intestine," Pharmaceutics, vol. 13, no. 1, p. 18, Dec. 2020, doi: 10.3390/pharmaceutics13010018.

[10] V. Andretto, A. Rosso, S. Briançon, and G. Lollo, "Nanocomposite Systems for Precise Oral Delivery of Drugs and Biologics," Drug Delivery and Translational Research, vol. 11, no. 2, pp. 445–470, Feb. 2021, doi: 10.1007/s13346-021-00905-w.